The global peripheral vascular devices market is projected to grow from USD 10.02 billion in 2026 to USD 13.22 billion by 2031 at a CAGR of 5.7%, driven by rising prevalence of vascular disorders, aging populations, and innovations in minimally invasive devices. Asia Pacific is expected to see the highest growth, with major players including Boston Scientific, Medtronic, and Abbott leading the market.

Ten large-cap stocks experienced significant declines during the week of May 25-29, 2026. Zscaler led losses with a 20.06% drop following disappointing Q3 results and weak Q4 guidance. Other major losers included Boston Scientific (16.95%), AutoZone (14.21%), Regencell Bioscience (12.61%), and Venture Global (10.87%). Declines were attributed to earnings misses, analyst downgrades, and energy sector weakness following geopolitical developments.

Boston Scientific announced a $1.5 billion investment for a 34% stake in MiRus LLC, gaining entry into the transcatheter aortic valve replacement (TAVR) market projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033. The deal includes an option to acquire the remaining stake for up to $3 billion if milestones are met. Wall Street remains bullish with 92% of analysts rating the stock a buy, while insider buying and a $2 billion share buyback signal management confidence.

The Dow Jones Industrial Average reached a record high above 50,600 while the Nasdaq 100 declined 0.7% on Wednesday. Oil prices fell sharply below $90 per barrel following reports of potential Iran negotiations, benefiting travel and leisure stocks. The S&P 500 edged slightly lower as semiconductor stocks retreated, while consumer discretionary and hospitality sectors led gains.

Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The trial of 420 patients achieved a 93.3% safety rate and 93.7% procedural success rate, exceeding pre-specified benchmarks. The device uses laser-generated acoustic pressure waves to fracture calcium buildup in coronary arteries before stent implantation.

Boston Scientific invested $1.5 billion in MiRus to acquire a 34% equity stake and exclusive option to acquire the SIEGEL Balloon Expandable TAVR system for treating severe aortic stenosis. The investigational device features a smaller delivery profile and advanced materials. Boston Scientific shares surged 5.56% on the announcement, though the stock remains down 42% year-to-date.

CNBC's Jim Cramer warns that while the current market is compared to the 1999 dot-com bubble, today's market is actually more brutal in punishing disappointing stocks. The market is heavily concentrated in AI and data center stocks while aggressively selling healthcare and medical technology companies that miss earnings expectations. Cramer defends AI investments as producing real business results, citing strong earnings from major tech companies.

Rosen Law Firm announces securities class action lawsuits against Boston Scientific Corporation, Camping World Holdings, Inc., and ADMA Biologics, Inc. The Boston Scientific lawsuit alleges the company made false statements about its U.S. Electrophysiology segment's sustainability while concealing material adverse facts, leading to a net income miss and underwhelming guidance. Investors who purchased shares during specified class periods are encouraged to join the litigation before upcoming deadlines.

A class action lawsuit has been filed against Boston Scientific Corporation alleging that the company made materially false and misleading statements regarding its U.S. electrophysiology segment's growth sustainability. The complaint claims management failed to disclose material adverse trends in procedure volumes, competitive pressures, and regulatory headwinds that negatively impacted the segment. Investors who purchased BSX securities between July 23, 2025, and February 3, 2026, are eligible to join the case.

A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment during July 23, 2025 to February 3, 2026. The lawsuit claims management concealed that the segment's growth was unsustainable and approaching an earlier decline than anticipated, leading to a net income miss and underwhelming guidance. Investors have until May 4, 2026 to serve as lead plaintiff.

Boston Scientific faces a class action lawsuit after its stock fell 17% on February 4, 2026, following the disclosure that fourth quarter GAAP net income of $0.45 per share missed its guidance range of $0.48-$0.52. The lawsuit alleges the company misled investors about its growth projections and failed to disclose competitive pressures from new entrants in the U.S. Electrophysiology market that undermined its ability to maintain 2x market growth.

A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment during July 23, 2025 to February 3, 2026. The lawsuit claims management concealed that the segment's growth was unsustainable and approaching an earlier decline than anticipated, leading to a net income miss and underwhelming guidance. Investors have until May 4, 2026 to serve as lead plaintiff.